Valuation: VACY AS

Market Cap 1.12B 0 118M 102M 95.88M 87.43M 165M 11.26B 167M 1.13B 441M 5.64B 443M 433M 18.81B P/E 2026 *
-5.23x
P/E 2027 * -36.5x
Enterprise Value 637M 0 66.97M 58.05M 54.42M 49.62M 93.36M 6.39B 94.86M 641M 250M 3.2B 251M 246M 10.67B EV / Sales 2026 *
-
EV / Sales 2027 * 3.37x
Free-Float
56.4%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 31/12/2018
President 49 31/12/2016
Director of Finance/CFO 51 02/05/2021
Director TitleAgeSince
Director/Board Member 54 -
Director/Board Member 57 -
Chairman 45 22/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 117M
+2.07%+10.05%+77.41%+106.53% 70.1B
-0.87%+0.77%+36.57%+65.91% 54.93B
-4.50%-4.69%+2.82%+466.50% 28.89B
+0.04%+12.56%+54.67%+5.47% 23.9B
-0.67%+1.02%-18.32%-14.26% 23.3B
+0.35%+8.24%+252.94%+466.50% 18.41B
-0.59%+7.03%+46.32%-20.56% 18.77B
-0.57%+6.85%+30.20%+580.70% 16.1B
+0.46%-3.05%+31.49%+135.29% 12.48B
Average -0.43%+8.19%+57.12%+199.12% 29.65B
Weighted average by Cap. -0.21%+8.03%+55.46%+163.38%

Financials

2026 *2027 *
Net sales - 162M 0 17.01M 14.75M 13.82M 12.6M 23.71M 1.62B 24.09M 163M 63.54M 813M 63.87M 62.48M 2.71B
Net income -208M -0 -21.87M -18.96M -17.77M -16.2M -30.49M -2.09B -30.98M -209M -81.69M -1.04B -82.11M -80.33M -3.49B -41.58M -0 -4.37M -3.79M -3.55M -3.24M -6.1M -417M -6.2M -41.85M -16.34M -209M -16.42M -16.07M -697M
Net Debt -485M -0 -51.03M -44.24M -41.47M -37.81M -71.14M -4.87B -72.28M -488M -191M -2.44B -192M -187M -8.13B -578M -0 -60.75M -52.66M -49.37M -45.01M -84.7M -5.8B -86.05M -581M -227M -2.9B -228M -223M -9.68B
Logo VACY AS
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.380NOK
Average target price
5.000NOK
Spread / Average Target
+47.93%

Quarterly revenue - Rate of surprise